Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CCKAR | P32238 | 2/20 | 0.36 |
| ▸ | CCKBR | P32239 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25877071 | 0.89 | AKT1 (0.44) | AKT1OPRM1OPRD1PSMB5 | |
| SCHEMBL25877257 | 0.89 | AKT1 (0.44) | AKT1OPRM1OPRD1PSMB5 | |
| SCHEMBL25877236 | 0.89 | AKT1 (0.44) | AKT1OPRM1OPRD1PSMB5 | |
| SCHEMBL20041046 | 0.86 | AKT1 (0.45) | AKT1OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL20345224 | 0.86 | AKT1 (0.45) | AKT1OPRM1OPRD1CHRNB2CHRNB4 | |
| SCHEMBL22757219 | 0.85 | AKT1 (0.47) | AKT1OPRM1OPRD1 | |
| SCHEMBL26348504 | 0.85 | AKT1 (0.45) | AKT1OPRM1OPRD1PSMB5 | |
| SCHEMBL25877172 | 0.85 | AKT1 (0.43) | AKT1CCKARCCKBR | |
| SCHEMBL26503041 | 0.84 | AKT1 (0.47) | AKT1OPRM1OPRD1FAAHPSMB5 | |
| SCHEMBL16983229 | 0.84 | AKT1 (0.47) | AKT1OPRM1OPRD1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | AKT1 2403/4885OPRM1 319/4885OPRD1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.